DPEP1 and COVID-19: While DPEP1’s nonenzymatic neutrophil-binding activity has been described in relation to sepsis and acute kidney injury with the LSALT peptide being used for COVID-19–related clinical trials, there have been no previous reports connecting its neutrophil-binding activity to cancer (16, 17, 69).